Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-23

Study Completion Date

2021-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Double-blind, randomized, placebo-controlled study to explore the safety, tolerability PK characteristics and early efficacy of ZSP1601 tablets in patients with non-alcoholic steatohepatitis (NASH).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05692492

Nonalcoholic Steatohepatitis (NASH)

ACTIVE_NOT_RECRUITING PHASE2

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

NCT03392779

Nonalcoholic Steatohepatitis (NASH)

COMPLETED PHASE1

A Phase II Clinical Trial of Chiglitazar for NASH

NCT05193916

NASH

COMPLETED PHASE2

Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

NCT05118360

Nonalcoholic Steatohepatitis (NASH)

WITHDRAWN PHASE2

A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects

NCT04913090

Nonalcoholic Steatohepatitis (NASH)

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Steatohepatitis (NASH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ZSP1601-Dose 1

ZSP1601-50mg once daily

Group Type EXPERIMENTAL

ZSP1601

Intervention Type DRUG

ZSP1601 tablets be taken orally for 28 days.

ZSP1601 Placebo

Intervention Type DRUG

Subjects will receive matching placebo of ZSP1601

ZSP1601-Dose 2

ZSP1601-50mg twice daily

Group Type EXPERIMENTAL

ZSP1601

Intervention Type DRUG

ZSP1601 tablets be taken orally for 28 days.

ZSP1601 Placebo

Intervention Type DRUG

Subjects will receive matching placebo of ZSP1601

ZSP1601-Dose 3

ZSP1601-100mg once daily

Group Type EXPERIMENTAL

ZSP1601

Intervention Type DRUG

ZSP1601 tablets be taken orally for 28 days.

ZSP1601 Placebo

Intervention Type DRUG

Subjects will receive matching placebo of ZSP1601

Placebo

Group Type PLACEBO_COMPARATOR

ZSP1601 Placebo

Intervention Type DRUG

Subjects will receive matching placebo of ZSP1601

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ZSP1601

ZSP1601 tablets be taken orally for 28 days.

Intervention Type DRUG

ZSP1601 Placebo

Subjects will receive matching placebo of ZSP1601

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects are required to meet the following criteria in order to be included in the trial:

1. Signature signed informed consent before the trial, and fully understood the content, process and possible adverse reactions.
2. Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
3. Subjects(including partners)have no gestation plans and must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.
4. Male and female subjects aged 18-65 (including 18 and 65).
5. B ultrasound confirmed fatty liver.
6. NASH diagnosis or NASH phenotypic diagnosis.
7. Liver fat ≥10% at baseline (MRI-PDFF)

Exclusion Criteria

1. Excessive drinking for 3 consecutive months within 1 year before screening.
2. Allergic constitution.
3. Subjects who donated blood or bleeding profusely(\> 400 mL)in the 3 months preceding study screening.
4. Subjects having a history of bariatric surgery or preparing for bariatric surgery recently.
5. Subjects having a history of liver transplantation or plans for liver transplantation
6. Any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers.
7. Liver biopsy indicates cirrhosis or previous clinical diagnosis of cirrhosis.
8. Type 1 diabetes mellitus.
9. Uncontrolled type 2 diabetes mellitus (HbA1c≥8.0%)。
10. Any clinically significant abnormality upon physical examination or in the clinical laboratory tests, history or presence of other causes of liver disease,but not limited to above disorders: hepatitis b or hepatitis c virus (HCV) infection and chronic alcoholic liver disease, drug-induced liver disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson 's disease, alpha 1 - antitrypsin deficiency, liver, obvious abnormal liver function (ALT and AST acuity 5 x ULN or TBIL acuity 1.5 x ULN), etc.
11. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.
12. History of having any special food(including dragon fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 2 weeks prior to screening.
13. Participated in another clinical research study and received any investigational products within 3 months prior to dosing.
14. Presence of clinically significant abnormalities in ECG or QTcB\>450ms in males,or QTcB\>470ms in females.
15. HIV positive.
16. Clinically significant nephropathy or renal dysfunction, blood creatinine \>1.5×ULN, eGFR\< 60 mL/min/1.73m2 \[calculation formula: Ccr:(140-age)× weight (kg) /0.818×Scr(mumol /L), female ×0.85\].
17. Platelet count \<100×109/L.
18. Antinuclear antibody (ANA) confirmed positive and clinically significant.
19. Abnormal TSH with clinical significance.
20. Female during pregnancy and lactation or positive serum pregnancy test.
21. Patients with contraindication of MRI scan.
22. Take any product contains alcohol within 24 hours prior to dosing.
23. Have chocolate, any food or beverage that contains caffeine or xanthine within 24 hours prior to dosing.
24. Positive for urine drug screening or history of substance abuse for a period of 5 consecutive years before screening.
25. Any acute illness or concomitant medication from screening to first dosing.
26. As judged by the researcher, it is not suitable to join the clinical researcher.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No